ImmunityBio (IBRX) Notes Payables (2014 - 2023)

ImmunityBio (IBRX) has 6 years of Notes Payables data on file, last reported at $481.9 million in Q2 2023.

• On a quarterly basis, Notes Payables rose 11489.56% year-over-year to $481.9 million in Q2 2023; TTM through Jun 2023 was $481.9 million, a 11489.56% increase from a year earlier, with the FY2022 full-year figure at $431.9 million, up 10853.61% from the prior year.
• Notes Payables for Q2 2023 stood at $481.9 million, up from $2.9 million in the prior quarter.
• Over the last five years, Notes Payables for IBRX reached as high as $481.9 million in Q2 2023 and fell as low as $2.9 million in Q1 2023.
• Historically, Notes Payables has averaged $155.3 million across 4 years, with a median of $9.5 million in 2020.
• On a YoY basis, Notes Payables climbed as much as 11489.56% in 2023 and fell as far as 99.02% in 2023.
• Year by year, Notes Payables stood at $14.8 million in 2020, then slumped by 73.43% to $3.9 million in 2021, then soared by 10853.61% to $431.9 million in 2022, then increased by 11.58% to $481.9 million in 2023.
• Per Business Quant data, the three most recent Notes Payables figures were $481.9 million in Q2 2023, $2.9 million in Q1 2023, and $431.9 million in Q4 2022.